The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10109 malaria professionals are enjoying the free benefits of MalariaWorld today

artemisinin combination therapies

NOT Open Access | Viability Screen of LOPAC1280 Reveals Tyrosine Kinase Inhibitor Tyrphostin A9 as a Novel Partner Drug for Artesunate Combinations To Target the Plasmodium falciparum Ring Stage

April 2, 2019 - 11:46 -- NOT Open Access
Jie Xin Tong, Sarah E. L. Ang, Esther H. N. Tan and Kevin S. W. Tan
Antimicrob Agents Chemother 63:e02389-18

The emergence of artemisinin-resistant Plasmodium falciparum poses a major threat to current frontline artemisinin combination therapies.

Efficacy and Tolerability Outcomes of a Phase II, Randomized, Open-Label, Multicenter Study of a New Water-Dispersible Pediatric Formulation of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in African Infa

December 27, 2017 - 12:49 -- Open Access
Nicola Gargano, Lola Madrid, Quique Bassat, et al.
Antimicrob. Agents Chemother. January 2018 vol. 62 no. 1 e00596-17

Artemisinin combination therapies are considered the mainstay of malaria treatment, but pediatric-friendly formulations for the treatment of infants are scarce.

NOT Open Access | Indolyl-3-ethanone-α-thioethers: A promising new class of non-toxic antimalarial agents

April 11, 2016 - 16:21 -- NOT Open Access
Archibald L. Svogie, Michelle Isaacs, Heinrich C. Hoppe, Setshaba D. Khanye, Clinton G.L. Veale
European Journal of Medicinal Chemistry, Volume 114, 23 May 2016, Pages 79–88

The success of chemotherapeutics in easing the burden of malaria is under continuous threat from ever-evolving parasite resistance, including resistance to artemisinin combination therapies.

Development, Evaluation, and Application of an In Silico Model for Antimalarial Drug Treatment and Failure

June 21, 2011 - 06:55 -- Kabogo Ndegwa
Katherine Winter and Ian M. Hastings
Antimicrobial Agents and Chemotherapy, July 2011,p. 3380-3392, Vol. 55, No. 7

Pharmacological mechanism-based modeling was refined and used to develop an in silico model of antimalarial drug treatment validated against clinical and field data.

Subscribe to RSS - artemisinin combination therapies